Replies to post #82379 on Anavex Life Sciences Corp (AVXL)

[NWDR]

Mapman,

Thanks for posting the info on the company timeline that 3-71 was ahead of 2-73 in Parkinson's disease. I had missed that and was wondering what the plan was for 3-71. 2-73 may be the first weapon to actually change the course of AZ and other CNS diseases. I'm cautiously hopeful that 3-71 will be a complete game changer... very very low doses required for efficacy signals. I'm hoping that in 2017 we see a first in human study with 3-71.

Cheers.

ps. History... cool, love history
pps. I'm old enough to have a gone to Woodstock but I was on a different coast. I should have still gone.
ppps. While not the original hippy I'm looking forward to reverting once I retire from my respectable trade.

Go AVXL.

pppps. When I first saw a picture of Dr. Missling I thought, "Can he get away with that hair?" Now I'm thinking, if he can, why can't I go back to my roots... so to speak.

Be well.